[{"orig_sen": "Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials.\r\n", "drug1": "fenofibric acid", "drug2": "fenofibrate", "polarity": ["false"]}, {"orig_sen": "Fenofibrate is a prodrug that is rapidly and completely hydrolyzed to fenofibric acid, the active moiety. ", "drug1": "Fenofibrate", "drug2": "fenofibric acid", "polarity": ["false"]}, {"orig_sen": "A new orally administered agent, fenofibric acid, was developed as an alternative to fenofibrate.", "drug1": "fenofibric acid", "drug2": "fenofibrate", "polarity": ["false"]}, {"orig_sen": "Two separate studies were conducted to evaluate the bioequivalence of fenofibric acid relative to fenofibrate under fasted and fed (standard breakfast) conditions, characterize the pharmacokinetic profile, and assess the safety and tolerability of fenofibric acid. ", "drug1": "fenofibric acid", "drug2": "fenofibrate", "polarity": ["false"]}, {"orig_sen": "Two separate studies were conducted to evaluate the bioequivalence of fenofibric acid relative to fenofibrate under fasted and fed (standard breakfast) conditions, characterize the pharmacokinetic profile, and assess the safety and tolerability of fenofibric acid. ", "drug1": "fenofibric acid", "drug2": "fenofibric acid", "polarity": ["false"]}, {"orig_sen": "Two separate studies were conducted to evaluate the bioequivalence of fenofibric acid relative to fenofibrate under fasted and fed (standard breakfast) conditions, characterize the pharmacokinetic profile, and assess the safety and tolerability of fenofibric acid. ", "drug1": "fenofibrate", "drug2": "fenofibric acid", "polarity": ["false"]}, {"orig_sen": "In study 1 (fasted), during each study period, volunteers received a single 105-mg dose of fenofibric acid or single 145-mg dose of fenofibrate (depending on their randomization scheme) after an overnight fast (a minimum fast of 10 hours). ", "drug1": "fenofibric acid", "drug2": "fenofibrate", "polarity": ["false"]}, {"orig_sen": "The criterion for a lack of difference between products was a 90% CI between 0.80 and 1.25 for the fenofibric acid:fenofibrate ratios for AUC(0-t), AUC(0-   ), and C(max.) ", "drug1": "fenofibric acid", "drug2": "fenofibrate", "polarity": ["false"]}, {"orig_sen": "The 90% CIs about the ratio of the fenofibric acid geometric mean to the fenofibrate geometric mean were within the 80% and 125% limits for the pharmacokinetic parameters C(max), AUC(0-t), and AUC(0-   ) of the ln-transformed data in both study 1 (fasted) and study 2. ", "drug1": "fenofibric acid", "drug2": "fenofibrate", "polarity": ["false"]}, {"orig_sen": "In these 2 single-dose studies, these healthy volunteers administered a single oral dose of 105-mg fenofibric acid met the US Food and Drug Administration regulatory criteria for assuming bioequivalence to a single oral dose of 145-mg fenofibrate tablets with respect to the rate and extent of fenofibric acid absorption in both fed and fasted states. ", "drug1": "fenofibric acid", "drug2": "fenofibrate", "polarity": ["false"]}, {"orig_sen": "In these 2 single-dose studies, these healthy volunteers administered a single oral dose of 105-mg fenofibric acid met the US Food and Drug Administration regulatory criteria for assuming bioequivalence to a single oral dose of 145-mg fenofibrate tablets with respect to the rate and extent of fenofibric acid absorption in both fed and fasted states. ", "drug1": "fenofibric acid", "drug2": "fenofibric acid", "polarity": ["false"]}, {"orig_sen": "In these 2 single-dose studies, these healthy volunteers administered a single oral dose of 105-mg fenofibric acid met the US Food and Drug Administration regulatory criteria for assuming bioequivalence to a single oral dose of 145-mg fenofibrate tablets with respect to the rate and extent of fenofibric acid absorption in both fed and fasted states. ", "drug1": "fenofibrate", "drug2": "fenofibric acid", "polarity": ["false"]}, {"orig_sen": "Conventional therapeutic drug monitoring based on measuring immunosupressive drug concentrations in blood is important in the clinical management of immunosuppressive therapy in transplantation medicine. ", "drug1": "immunosupressive drug", "drug2": "immunosuppressive", "polarity": ["false"]}, {"orig_sen": "The treatment of coinfected patients requires antituberculosis and antiretroviral drugs to be administered concomittantly; ", "drug1": "antituberculosis drugs", "drug2": "antiretroviral drugs", "polarity": ["false"]}, {"orig_sen": "Current guidelines recommend starting antiretroviral treatment within a few weeks of antituberculosis therapy for patients with CD4 cell counts", "drug1": "antiretroviral", "drug2": "antituberculosis", "polarity": ["false"]}, {"orig_sen": "Effects of neferine on the pharmacokinetics of amiodarone in rats.\r\n", "drug1": "neferine", "drug2": "amiodarone", "polarity": ["false"]}, {"orig_sen": "The purpose of this study was to assess the potential of neferine, an effective anti-pulmonary fibrosis drug isolated from the embryo of Nelumbo nucifera Gaertner's seeds, to alter the pharmacokinetic profile of amiodarone. ", "drug1": "neferine", "drug2": "amiodarone", "polarity": ["false"]}, {"orig_sen": "In groups 1 and 2, amiodarone was given to rats by intragastric and intravenous administration, respectively, while neferine was co-administratered by intragastric administration. ", "drug1": "amiodarone", "drug2": "neferine", "polarity": ["false"]}, {"orig_sen": "There were no significant differences between the pharmacokinetics parameters of amiodarone administered intravenously or intragastrically and the control (without neferine) group (with ratios of 0.7-1.4 in all experimental groups), suggesting that neferine had no effect on amiodarone plasma pharmacokinetics. ", "drug1": "amiodarone", "drug2": "neferine", "polarity": ["false", "false"]}, {"orig_sen": "There were no significant differences between the pharmacokinetics parameters of amiodarone administered intravenously or intragastrically and the control (without neferine) group (with ratios of 0.7-1.4 in all experimental groups), suggesting that neferine had no effect on amiodarone plasma pharmacokinetics. ", "drug1": "amiodarone", "drug2": "amiodarone", "polarity": ["false"]}, {"orig_sen": "There were no significant differences between the pharmacokinetics parameters of amiodarone administered intravenously or intragastrically and the control (without neferine) group (with ratios of 0.7-1.4 in all experimental groups), suggesting that neferine had no effect on amiodarone plasma pharmacokinetics. ", "drug1": "neferine", "drug2": "neferine", "polarity": ["false"]}, {"orig_sen": "There were no significant differences between the pharmacokinetics parameters of amiodarone administered intravenously or intragastrically and the control (without neferine) group (with ratios of 0.7-1.4 in all experimental groups), suggesting that neferine had no effect on amiodarone plasma pharmacokinetics. ", "drug1": "neferine", "drug2": "amiodarone", "polarity": ["false", "false"]}, {"orig_sen": "The dosage regimen of amiodarone does not need to be taken into consideration when combined with neferine.", "drug1": "amiodarone", "drug2": "neferine", "polarity": ["false"]}, {"orig_sen": "We observed that GLIC recapitulates bimodal modulation by n-alcohols, similar to some eukaryotic pLGICs: methanol and ethanol weakly potentiated proton-activated currents in GLIC, whereas n-alcohols larger than ethanol inhibited them. ", "drug1": "methanol", "drug2": "ethanol", "polarity": ["false"]}, {"orig_sen": "Mapping of residues important to alcohol modulation of ionotropic receptors for glycine,   -aminobutyric acid, and acetylcholine onto GLIC revealed their proximity to transmembrane cavities that may accommodate one or more alcohol molecules. ", "drug1": "alcohol", "drug2": "alcohol", "polarity": ["false"]}, {"orig_sen": "Neuropharmacological approach against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine)-induced mouse model of Parkinson's disease.\r\n", "drug1": "MPTP", "drug2": "1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine", "polarity": ["false"]}, {"orig_sen": "The biochemical and cellular alterations that occur after 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment are remarkably similar to that observed in idiopathic PD. ", "drug1": "1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine", "drug2": "MPTP", "polarity": ["false"]}, {"orig_sen": "Furthermore, it is well known that acute treatment with MPTP can cause a severe loss of tyrosine hydroxylase and dopamine transporter protein levels and dopamine contents in the striatum of mice, as compared to continuous MPTP treatment. ", "drug1": "MPTP", "drug2": "MPTP", "polarity": ["false"]}, {"orig_sen": "We sought to determine (1) the frequency of colchicine toxicity among hospitalized patients taking colchicine who died during an admission, (2) the likelihood that colchicine contributed to death, (3) whether patients were taking interacting medications that could have contributed to toxicity, and (4) whether colchicine dosing among these patients adhered to established guidelines. ", "drug1": "colchicine", "drug2": "colchicine", "polarity": ["false", "false", "false", "false", "false", "false"]}, {"orig_sen": "An expert panel reviewed each case and classified the likelihood of colchicine toxicity, the likelihood of a causal role of colchicine in the death using the WHO classification system, and the appropriateness of colchicine dosing. ", "drug1": "colchicine", "drug2": "colchicine", "polarity": ["false", "false", "false"]}, {"orig_sen": "According to the calculated level of risk, guidelines recommend patients with atrial fibrillation receive antithrombotic therapy either as a vitamin K antagonist or aspirin. ", "drug1": "antithrombotic", "drug2": "vitamin K antagonist", "polarity": ["false"]}, {"orig_sen": "According to the calculated level of risk, guidelines recommend patients with atrial fibrillation receive antithrombotic therapy either as a vitamin K antagonist or aspirin. ", "drug1": "antithrombotic", "drug2": "aspirin", "polarity": ["false"]}, {"orig_sen": "According to the calculated level of risk, guidelines recommend patients with atrial fibrillation receive antithrombotic therapy either as a vitamin K antagonist or aspirin. ", "drug1": "vitamin K antagonist", "drug2": "aspirin", "polarity": ["false"]}, {"orig_sen": "The novel oral anticoagulants in development may overcome some of the limitations of vitamin K antagonists and address their underuse and safety concerns.", "drug1": "anticoagulants", "drug2": "vitamin K antagonists", "polarity": ["false"]}, {"orig_sen": "All mRPCs of 20 passages or less were transplanted into the subretinal space of B6 mice together with chondroitinase ABC, and into Rho(-/-) mice combined with chondroitinase ABC, N-[N-(3, 5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), and insulin growth factor (IGF)-1. ", "drug1": "N-[N-(3, 5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester", "drug2": "DAPT", "polarity": ["false"]}, {"orig_sen": "All mRPCs of 20 passages or less were transplanted into the subretinal space of B6 mice together with chondroitinase ABC, and into Rho(-/-) mice combined with chondroitinase ABC, N-[N-(3, 5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), and insulin growth factor (IGF)-1. ", "drug1": "N-[N-(3, 5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester", "drug2": "insulin growth factor", "polarity": ["false"]}, {"orig_sen": "All mRPCs of 20 passages or less were transplanted into the subretinal space of B6 mice together with chondroitinase ABC, and into Rho(-/-) mice combined with chondroitinase ABC, N-[N-(3, 5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), and insulin growth factor (IGF)-1. ", "drug1": "N-[N-(3, 5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester", "drug2": "(IGF)-1", "polarity": ["false"]}, {"orig_sen": "All mRPCs of 20 passages or less were transplanted into the subretinal space of B6 mice together with chondroitinase ABC, and into Rho(-/-) mice combined with chondroitinase ABC, N-[N-(3, 5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), and insulin growth factor (IGF)-1. ", "drug1": "DAPT", "drug2": "insulin growth factor", "polarity": ["false"]}, {"orig_sen": "All mRPCs of 20 passages or less were transplanted into the subretinal space of B6 mice together with chondroitinase ABC, and into Rho(-/-) mice combined with chondroitinase ABC, N-[N-(3, 5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), and insulin growth factor (IGF)-1. ", "drug1": "DAPT", "drug2": "(IGF)-1", "polarity": ["false"]}, {"orig_sen": "All mRPCs of 20 passages or less were transplanted into the subretinal space of B6 mice together with chondroitinase ABC, and into Rho(-/-) mice combined with chondroitinase ABC, N-[N-(3, 5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), and insulin growth factor (IGF)-1. ", "drug1": "insulin growth factor", "drug2": "(IGF)-1", "polarity": ["false"]}, {"orig_sen": "The risk of gastrointestinal bleeding during the treatment with antiagregants and anticoagulants, the risk of bradycardia in beta-blockade, possible interactions with other medications lowering the heart rate are discussed. ", "drug1": "antiagregants", "drug2": "anticoagulants", "polarity": ["false"]}, {"orig_sen": "Attention is paid to calcium channel blockers, diuretics and digoxin. ", "drug1": "calcium channel blockers", "drug2": "diuretics", "polarity": ["false"]}, {"orig_sen": "Attention is paid to calcium channel blockers, diuretics and digoxin. ", "drug1": "calcium channel blockers", "drug2": "digoxin", "polarity": ["false"]}, {"orig_sen": "Attention is paid to calcium channel blockers, diuretics and digoxin. ", "drug1": "diuretics", "drug2": "digoxin", "polarity": ["false"]}, {"orig_sen": "Post-exposure prophylaxis for H1N1 with oseltamivir in renal allograft recipient--safe and effective without any immunosuppresive drug interaction.\r\n", "drug1": "oseltamivir", "drug2": "immunosuppresive drug", "polarity": ["false"]}, {"orig_sen": "Post-exposure prophylaxis of H1N1 with oseltamivir was safe, effective and well tolerated to prevent H1N1 influenza A virus infection in newly transplanted renal allograft recipient receiving triple immunosuppression without any interaction with tacrolimus level. ", "drug1": "oseltamivir", "drug2": "tacrolimus", "polarity": ["false"]}, {"orig_sen": "Improvement of colchicine oral bioavailability by incorporating eugenol in the nanoemulsion as an oil excipient and enhancer.\r\n", "drug1": "colchicine", "drug2": "eugenol", "polarity": ["false"]}, {"orig_sen": "The effect of eugenol on colchicine transport across an isolated rat intestinal membrane was studied using an in vitro diffusion chamber system. ", "drug1": "eugenol", "drug2": "colchicine", "polarity": ["false"]}, {"orig_sen": "The effect of eugenol on intestinal absorption of colchicine in an oral administrative nanoemulsion formulation was also demonstrated in vivo. ", "drug1": "eugenol", "drug2": "colchicine", "polarity": ["false"]}, {"orig_sen": "The colchicine nanoemulsion was prepared with isopropyl myristate, eugenol, Tween80, ethanol and water, and eugenol was used as an oil phase in the formulation; ", "drug1": "colchicine", "drug2": "isopropyl myristate", "polarity": ["false"]}, {"orig_sen": "The colchicine nanoemulsion was prepared with isopropyl myristate, eugenol, Tween80, ethanol and water, and eugenol was used as an oil phase in the formulation; ", "drug1": "colchicine", "drug2": "eugenol", "polarity": ["false", "false"]}, {"orig_sen": "The colchicine nanoemulsion was prepared with isopropyl myristate, eugenol, Tween80, ethanol and water, and eugenol was used as an oil phase in the formulation; ", "drug1": "colchicine", "drug2": "Tween80", "polarity": ["false"]}, {"orig_sen": "The colchicine nanoemulsion was prepared with isopropyl myristate, eugenol, Tween80, ethanol and water, and eugenol was used as an oil phase in the formulation; ", "drug1": "colchicine", "drug2": "ethanol", "polarity": ["false"]}, {"orig_sen": "The colchicine nanoemulsion was prepared with isopropyl myristate, eugenol, Tween80, ethanol and water, and eugenol was used as an oil phase in the formulation; ", "drug1": "isopropyl myristate", "drug2": "eugenol", "polarity": ["false", "false"]}, {"orig_sen": "The colchicine nanoemulsion was prepared with isopropyl myristate, eugenol, Tween80, ethanol and water, and eugenol was used as an oil phase in the formulation; ", "drug1": "isopropyl myristate", "drug2": "Tween80", "polarity": ["false"]}, {"orig_sen": "The colchicine nanoemulsion was prepared with isopropyl myristate, eugenol, Tween80, ethanol and water, and eugenol was used as an oil phase in the formulation; ", "drug1": "isopropyl myristate", "drug2": "ethanol", "polarity": ["false"]}, {"orig_sen": "The colchicine nanoemulsion was prepared with isopropyl myristate, eugenol, Tween80, ethanol and water, and eugenol was used as an oil phase in the formulation; ", "drug1": "eugenol", "drug2": "Tween80", "polarity": ["false"]}, {"orig_sen": "The colchicine nanoemulsion was prepared with isopropyl myristate, eugenol, Tween80, ethanol and water, and eugenol was used as an oil phase in the formulation; ", "drug1": "eugenol", "drug2": "ethanol", "polarity": ["false"]}, {"orig_sen": "The colchicine nanoemulsion was prepared with isopropyl myristate, eugenol, Tween80, ethanol and water, and eugenol was used as an oil phase in the formulation; ", "drug1": "eugenol", "drug2": "eugenol", "polarity": ["false"]}, {"orig_sen": "The colchicine nanoemulsion was prepared with isopropyl myristate, eugenol, Tween80, ethanol and water, and eugenol was used as an oil phase in the formulation; ", "drug1": "Tween80", "drug2": "ethanol", "polarity": ["false"]}, {"orig_sen": "The colchicine nanoemulsion was prepared with isopropyl myristate, eugenol, Tween80, ethanol and water, and eugenol was used as an oil phase in the formulation; ", "drug1": "Tween80", "drug2": "eugenol", "polarity": ["false"]}, {"orig_sen": "The colchicine nanoemulsion was prepared with isopropyl myristate, eugenol, Tween80, ethanol and water, and eugenol was used as an oil phase in the formulation; ", "drug1": "ethanol", "drug2": "eugenol", "polarity": ["false"]}, {"orig_sen": "The permeation of colchicine in the nanoemulsion across the intestinal membrane was significantly different from that of the control group (0.2 mM colchicine). ", "drug1": "colchicine", "drug2": "colchicine", "polarity": ["false"]}, {"orig_sen": "Finally, co-administration of eugenol in colchicine nanoemulsion to enhance the colchicine bioavailability was investigated by an oral administration method. ", "drug1": "eugenol", "drug2": "colchicine", "polarity": ["false", "false"]}, {"orig_sen": "Finally, co-administration of eugenol in colchicine nanoemulsion to enhance the colchicine bioavailability was investigated by an oral administration method. ", "drug1": "colchicine", "drug2": "colchicine", "polarity": ["false"]}, {"orig_sen": "After oral administration of colchicine (8 mg/kg) in the form of either the nanoemulsion or in free colchicine solution, the relative bioavailability of nanoemulsion and eugenol-nanoemulsion were enhanced by about 1.6- and 2.1-fold, respectively, compared with free colchicine solution. ", "drug1": "colchicine", "drug2": "colchicine", "polarity": ["false", "false", "false"]}, {"orig_sen": "After oral administration of colchicine (8 mg/kg) in the form of either the nanoemulsion or in free colchicine solution, the relative bioavailability of nanoemulsion and eugenol-nanoemulsion were enhanced by about 1.6- and 2.1-fold, respectively, compared with free colchicine solution. ", "drug1": "colchicine", "drug2": "eugenol", "polarity": ["false", "false"]}, {"orig_sen": "After oral administration of colchicine (8 mg/kg) in the form of either the nanoemulsion or in free colchicine solution, the relative bioavailability of nanoemulsion and eugenol-nanoemulsion were enhanced by about 1.6- and 2.1-fold, respectively, compared with free colchicine solution. ", "drug1": "eugenol", "drug2": "colchicine", "polarity": ["false"]}, {"orig_sen": "The procedure indicated that the intestinal absorption of colchicine was enhanced significantly by eugenol in the tested nanoemulsion. ", "drug1": "colchicine", "drug2": "eugenol", "polarity": ["false"]}, {"orig_sen": "All the results suggested that eugenol is an efficient component in an oral administrative formulation for improving the intestinal absorption of colchicine.", "drug1": "eugenol", "drug2": "colchicine", "polarity": ["false"]}, {"orig_sen": "[Protective effects of ginseng-ginko extracts combination on rat primary cultured neurons induced by Abeta(1-40)].\r\n", "drug1": "ginseng", "drug2": "ginko", "polarity": ["false"]}, {"orig_sen": "[Protective effects of ginseng-ginko extracts combination on rat primary cultured neurons induced by Abeta(1-40)].\r\n", "drug1": "ginseng", "drug2": "Abeta(1-40)", "polarity": ["false"]}, {"orig_sen": "[Protective effects of ginseng-ginko extracts combination on rat primary cultured neurons induced by Abeta(1-40)].\r\n", "drug1": "ginko", "drug2": "Abeta(1-40)", "polarity": ["false"]}, {"orig_sen": "To observe the injury in rat primary cultured neurons induced by Abeta(1-40) and the protective effects of combination of ginseng and ginko extracts.", "drug1": "Abeta(1-40)", "drug2": "ginseng", "polarity": ["false"]}, {"orig_sen": "To observe the injury in rat primary cultured neurons induced by Abeta(1-40) and the protective effects of combination of ginseng and ginko extracts.", "drug1": "Abeta(1-40)", "drug2": "ginko", "polarity": ["false"]}, {"orig_sen": "To observe the injury in rat primary cultured neurons induced by Abeta(1-40) and the protective effects of combination of ginseng and ginko extracts.", "drug1": "ginseng", "drug2": "ginko", "polarity": ["false"]}, {"orig_sen": "The effects of extracts of ginseng and ginko (EGGB) on cellular proliferative activity, apoptotic rate, ultrastructure and caspase-3 expression were detected. ", "drug1": "ginseng", "drug2": "ginko", "polarity": ["false"]}, {"orig_sen": "The effects of extracts of ginseng and ginko (EGGB) on cellular proliferative activity, apoptotic rate, ultrastructure and caspase-3 expression were detected. ", "drug1": "ginseng", "drug2": "EGGB", "polarity": ["false"]}, {"orig_sen": "The effects of extracts of ginseng and ginko (EGGB) on cellular proliferative activity, apoptotic rate, ultrastructure and caspase-3 expression were detected. ", "drug1": "ginko", "drug2": "EGGB", "polarity": ["false"]}, {"orig_sen": "[Effects of glycyrrhiza extract on pharmacokinetics property of daphnetin in rats].\r\n", "drug1": "glycyrrhiza extract", "drug2": "daphnetin", "polarity": ["false"]}, {"orig_sen": "To research the influence of glycyrrhiza extract on the pharmacokinetics characteristic parameters of daphnetin, which was aimed to explore the rationality of concert application of drugs.", "drug1": "glycyrrhiza extract", "drug2": "daphnetin", "polarity": ["false"]}, {"orig_sen": "The rats received intragastric administration of daphnetin and glycyrrhiza extract containing the same daphnetin respectively. ", "drug1": "daphnetin", "drug2": "glycyrrhiza extract", "polarity": ["false"]}, {"orig_sen": "The rats received intragastric administration of daphnetin and glycyrrhiza extract containing the same daphnetin respectively. ", "drug1": "daphnetin", "drug2": "daphnetin", "polarity": ["false"]}, {"orig_sen": "The rats received intragastric administration of daphnetin and glycyrrhiza extract containing the same daphnetin respectively. ", "drug1": "glycyrrhiza extract", "drug2": "daphnetin", "polarity": ["false"]}, {"orig_sen": "Antimicrobial effects of o-cymen-5-ol and zinc, alone &", "drug1": "o-cymen-5-ol", "drug2": "zinc", "polarity": ["false"]}, {"orig_sen": "This study aimed to evaluate antimicrobial effects of an o-cymen-5-ol/zinc system.", "drug1": "o-cymen-5-ol", "drug2": "zinc", "polarity": ["false"]}, {"orig_sen": "o-Cymen-5-ol and zinc gluconate minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were determined against Streptococcus mutans, Actinomyces viscosus, Porphyromonas gingivalis, Fusobacterium nucleatum and Candida albicans. ", "drug1": "o-Cymen-5-ol", "drug2": "zinc gluconate", "polarity": ["false"]}, {"orig_sen": "nucleatum, with MIC of 0.42 mM/0.69 mM for o-cymen-5-ol/zinc gluconate, respectively. ", "drug1": "o-cymen-5-ol", "drug2": "zinc gluconate", "polarity": ["false"]}, {"orig_sen": "Zinc inhibited glycolysis and protease to a greater degree than o-cymen-5-ol; ", "drug1": "Zinc", "drug2": "o-cymen-5-ol", "polarity": ["false"]}, {"orig_sen": "o-Cymen-5-ol/zinc chloride in toothpaste showed greater effects than placebo (120s log10 kill=7.35  0.40 and 4.02  0.40, respectively). ", "drug1": "o-Cymen-5-ol", "drug2": "zinc chloride", "polarity": ["false"]}, {"orig_sen": "The zinc/o-cymen-5-ol system has direct antimicrobial effects and inhibits oral disease-related processes. ", "drug1": "zinc", "drug2": "o-cymen-5-ol", "polarity": ["false"]}, {"orig_sen": "A system combining o-cymen-5-ol and zinc shows properties desirable for incorporation in toothpastes.", "drug1": "o-cymen-5-ol", "drug2": "zinc", "polarity": ["false"]}, {"orig_sen": "Co-administration of moxidectin with inhibitors of ABC transporter function did not enhance sensitivity to moxidectin in males; ", "drug1": "moxidectin", "drug2": "moxidectin", "polarity": ["false"]}, {"orig_sen": "The aim of this study was to assess the influence of manganese gluconate, a chemical activator of bleaching agents, at a concentration of 0.01% on the efficiency of a 10% carbamide peroxide-based bleaching agent. ", "drug1": "manganese gluconate", "drug2": "carbamide peroxide", "polarity": ["false"]}, {"orig_sen": "Group 2 consisted of 10% carbamide peroxide-based bleaching gel and 0.01% manganese gluconate. ", "drug1": "carbamide peroxide", "drug2": "manganese gluconate", "polarity": ["false"]}, {"orig_sen": "Adding 0.01% manganese gluconate to 10% carbamide peroxide bleaching gel increased the degree of tooth bleaching after a seven-day treatment and did not influence the resulting shade after 14 days.", "drug1": "manganese gluconate", "drug2": "carbamide peroxide", "polarity": ["false"]}, {"orig_sen": "An increase in serum osmolality and serum osmolal gap with or without high-anion-gap metabolic acidosis is an important clue to exposure to one of the toxic alcohols, which include methanol, ethylene glycol, diethylene glycol, propylene glycol, or isopropanol. ", "drug1": "methanol", "drug2": "ethylene glycol", "polarity": ["false"]}, {"orig_sen": "An increase in serum osmolality and serum osmolal gap with or without high-anion-gap metabolic acidosis is an important clue to exposure to one of the toxic alcohols, which include methanol, ethylene glycol, diethylene glycol, propylene glycol, or isopropanol. ", "drug1": "methanol", "drug2": "diethylene glycol", "polarity": ["false"]}, {"orig_sen": "An increase in serum osmolality and serum osmolal gap with or without high-anion-gap metabolic acidosis is an important clue to exposure to one of the toxic alcohols, which include methanol, ethylene glycol, diethylene glycol, propylene glycol, or isopropanol. ", "drug1": "methanol", "drug2": "propylene glycol", "polarity": ["false"]}, {"orig_sen": "An increase in serum osmolality and serum osmolal gap with or without high-anion-gap metabolic acidosis is an important clue to exposure to one of the toxic alcohols, which include methanol, ethylene glycol, diethylene glycol, propylene glycol, or isopropanol. ", "drug1": "methanol", "drug2": "isopropanol", "polarity": ["false"]}, {"orig_sen": "An increase in serum osmolality and serum osmolal gap with or without high-anion-gap metabolic acidosis is an important clue to exposure to one of the toxic alcohols, which include methanol, ethylene glycol, diethylene glycol, propylene glycol, or isopropanol. ", "drug1": "ethylene glycol", "drug2": "diethylene glycol", "polarity": ["false"]}, {"orig_sen": "An increase in serum osmolality and serum osmolal gap with or without high-anion-gap metabolic acidosis is an important clue to exposure to one of the toxic alcohols, which include methanol, ethylene glycol, diethylene glycol, propylene glycol, or isopropanol. ", "drug1": "ethylene glycol", "drug2": "propylene glycol", "polarity": ["false"]}, {"orig_sen": "An increase in serum osmolality and serum osmolal gap with or without high-anion-gap metabolic acidosis is an important clue to exposure to one of the toxic alcohols, which include methanol, ethylene glycol, diethylene glycol, propylene glycol, or isopropanol. ", "drug1": "ethylene glycol", "drug2": "isopropanol", "polarity": ["false"]}, {"orig_sen": "An increase in serum osmolality and serum osmolal gap with or without high-anion-gap metabolic acidosis is an important clue to exposure to one of the toxic alcohols, which include methanol, ethylene glycol, diethylene glycol, propylene glycol, or isopropanol. ", "drug1": "diethylene glycol", "drug2": "propylene glycol", "polarity": ["false"]}, {"orig_sen": "An increase in serum osmolality and serum osmolal gap with or without high-anion-gap metabolic acidosis is an important clue to exposure to one of the toxic alcohols, which include methanol, ethylene glycol, diethylene glycol, propylene glycol, or isopropanol. ", "drug1": "diethylene glycol", "drug2": "isopropanol", "polarity": ["false"]}, {"orig_sen": "An increase in serum osmolality and serum osmolal gap with or without high-anion-gap metabolic acidosis is an important clue to exposure to one of the toxic alcohols, which include methanol, ethylene glycol, diethylene glycol, propylene glycol, or isopropanol. ", "drug1": "propylene glycol", "drug2": "isopropanol", "polarity": ["false"]}, {"orig_sen": "[Ticagrelor: a novel antiplatelet agent for patients with acute coronary syndrome].\r\n", "drug1": "Ticagrelor", "drug2": "antiplatelet agent", "polarity": ["false"]}, {"orig_sen": "In clinical trials the antiplatelet agent reduced significantly vascular mortality and death from any cause when compared to clopidogrel in patients with acute coronary syndrome.", "drug1": "antiplatelet agent", "drug2": "clopidogrel", "polarity": ["false"]}, {"orig_sen": "In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an integrase inhibitor (II) is recommended. ", "drug1": "nucleoside or nucleotide reverse transcriptase inhibitors", "drug2": "NRTI", "polarity": ["false"]}, {"orig_sen": "In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an integrase inhibitor (II) is recommended. ", "drug1": "nucleoside or nucleotide reverse transcriptase inhibitors", "drug2": "non-nucleoside reverse transcriptase inhibitor", "polarity": ["false"]}, {"orig_sen": "In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an integrase inhibitor (II) is recommended. ", "drug1": "nucleoside or nucleotide reverse transcriptase inhibitors", "drug2": "NNRTI", "polarity": ["false"]}, {"orig_sen": "In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an integrase inhibitor (II) is recommended. ", "drug1": "nucleoside or nucleotide reverse transcriptase inhibitors", "drug2": "protease inhibitor", "polarity": ["false"]}, {"orig_sen": "In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an integrase inhibitor (II) is recommended. ", "drug1": "nucleoside or nucleotide reverse transcriptase inhibitors", "drug2": "PI", "polarity": ["false"]}, {"orig_sen": "In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an integrase inhibitor (II) is recommended. ", "drug1": "nucleoside or nucleotide reverse transcriptase inhibitors", "drug2": "integrase inhibitor", "polarity": ["false"]}, {"orig_sen": "In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an integrase inhibitor (II) is recommended. ", "drug1": "nucleoside or nucleotide reverse transcriptase inhibitors", "drug2": "II", "polarity": ["false"]}, {"orig_sen": "In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an integrase inhibitor (II) is recommended. ", "drug1": "NRTI", "drug2": "non-nucleoside reverse transcriptase inhibitor", "polarity": ["false"]}, {"orig_sen": "In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an integrase inhibitor (II) is recommended. ", "drug1": "NRTI", "drug2": "NNRTI", "polarity": ["false"]}, {"orig_sen": "In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an integrase inhibitor (II) is recommended. ", "drug1": "NRTI", "drug2": "protease inhibitor", "polarity": ["false"]}, {"orig_sen": "In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an integrase inhibitor (II) is recommended. ", "drug1": "NRTI", "drug2": "PI", "polarity": ["false"]}, {"orig_sen": "In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an integrase inhibitor (II) is recommended. ", "drug1": "NRTI", "drug2": "integrase inhibitor", "polarity": ["false"]}, {"orig_sen": "In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an integrase inhibitor (II) is recommended. ", "drug1": "NRTI", "drug2": "II", "polarity": ["false"]}, {"orig_sen": "In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an integrase inhibitor (II) is recommended. ", "drug1": "non-nucleoside reverse transcriptase inhibitor", "drug2": "NNRTI", "polarity": ["false"]}, {"orig_sen": "In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an integrase inhibitor (II) is recommended. ", "drug1": "non-nucleoside reverse transcriptase inhibitor", "drug2": "protease inhibitor", "polarity": ["false"]}, {"orig_sen": "In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an integrase inhibitor (II) is recommended. ", "drug1": "non-nucleoside reverse transcriptase inhibitor", "drug2": "PI", "polarity": ["false"]}, {"orig_sen": "In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an integrase inhibitor (II) is recommended. ", "drug1": "non-nucleoside reverse transcriptase inhibitor", "drug2": "integrase inhibitor", "polarity": ["false"]}, {"orig_sen": "In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an integrase inhibitor (II) is recommended. ", "drug1": "non-nucleoside reverse transcriptase inhibitor", "drug2": "II", "polarity": ["false"]}, {"orig_sen": "In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an integrase inhibitor (II) is recommended. ", "drug1": "NNRTI", "drug2": "protease inhibitor", "polarity": ["false"]}, {"orig_sen": "In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an integrase inhibitor (II) is recommended. ", "drug1": "NNRTI", "drug2": "PI", "polarity": ["false"]}, {"orig_sen": "In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an integrase inhibitor (II) is recommended. ", "drug1": "NNRTI", "drug2": "integrase inhibitor", "polarity": ["false"]}, {"orig_sen": "In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an integrase inhibitor (II) is recommended. ", "drug1": "NNRTI", "drug2": "II", "polarity": ["false"]}, {"orig_sen": "In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an integrase inhibitor (II) is recommended. ", "drug1": "protease inhibitor", "drug2": "PI", "polarity": ["false"]}, {"orig_sen": "In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an integrase inhibitor (II) is recommended. ", "drug1": "protease inhibitor", "drug2": "integrase inhibitor", "polarity": ["false"]}, {"orig_sen": "In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an integrase inhibitor (II) is recommended. ", "drug1": "protease inhibitor", "drug2": "II", "polarity": ["false"]}, {"orig_sen": "In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an integrase inhibitor (II) is recommended. ", "drug1": "PI", "drug2": "integrase inhibitor", "polarity": ["false"]}, {"orig_sen": "In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an integrase inhibitor (II) is recommended. ", "drug1": "PI", "drug2": "II", "polarity": ["false"]}, {"orig_sen": "In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an integrase inhibitor (II) is recommended. ", "drug1": "integrase inhibitor", "drug2": "II", "polarity": ["false"]}, {"orig_sen": "Before and during antiretroviral treatment, antiretroviral drug resistances, individual tolerance profiles and the needs of the individual patient, as well as several interactions with other drugs have to be considered. ", "drug1": "antiretroviral", "drug2": "antiretroviral", "polarity": ["false"]}, {"orig_sen": "In direct contrast, in rats made opiate dependent and conditioned in a state of withdrawal, intra-BLA D2, but not D1, receptor blockade blocked opiate reward encoding. ", "drug1": "opiate", "drug2": "opiate", "polarity": ["false"]}, {"orig_sen": "Single-unit in vivo extracellular recordings performed in neurons of the NAc confirmed an opiate-state-dependent role for BLA D1/D2 transmission in NAc neuronal response patterns to morphine. ", "drug1": "opiate", "drug2": "morphine", "polarity": ["false"]}, {"orig_sen": "Our results characterize and identify a novel opiate addiction switching mechanism directly in the BLA that can control the processing of opiate reward information as a direct function of opiate exposure state via D1 or D2 receptor signaling substrates.", "drug1": "opiate", "drug2": "opiate", "polarity": ["false", "false", "false"]}, {"orig_sen": "Selective serotonin reuptake inhibitors were the most commonly prescribed antidepressant. ", "drug1": "Selective serotonin reuptake inhibitors", "drug2": "antidepressant", "polarity": ["false"]}, {"orig_sen": "Having moderate to severe pain (ARRR=1.54, 95% CI=1.08-2.20) and the prescribing of an anxiolytic or hypnotic (ARRR=1.33, 95% CI=1.02-1.74) increased the risk of potential inappropriate antidepressant use. ", "drug1": "anxiolytic", "drug2": "hypnotic", "polarity": ["false"]}, {"orig_sen": "Having moderate to severe pain (ARRR=1.54, 95% CI=1.08-2.20) and the prescribing of an anxiolytic or hypnotic (ARRR=1.33, 95% CI=1.02-1.74) increased the risk of potential inappropriate antidepressant use. ", "drug1": "anxiolytic", "drug2": "antidepressant", "polarity": ["false"]}, {"orig_sen": "Having moderate to severe pain (ARRR=1.54, 95% CI=1.08-2.20) and the prescribing of an anxiolytic or hypnotic (ARRR=1.33, 95% CI=1.02-1.74) increased the risk of potential inappropriate antidepressant use. ", "drug1": "hypnotic", "drug2": "antidepressant", "polarity": ["false"]}, {"orig_sen": "Treatment of nicotine dependence with Chantix (varenicline).\r\n", "drug1": "nicotine", "drug2": "Chantix", "polarity": ["false"]}, {"orig_sen": "Treatment of nicotine dependence with Chantix (varenicline).\r\n", "drug1": "nicotine", "drug2": "varenicline", "polarity": ["false"]}, {"orig_sen": "Treatment of nicotine dependence with Chantix (varenicline).\r\n", "drug1": "Chantix", "drug2": "varenicline", "polarity": ["false"]}, {"orig_sen": "Varenicline is the generic name for Chantix, the newest drug available for the treatment of tobacco dependence. ", "drug1": "Varenicline", "drug2": "Chantix", "polarity": ["false"]}, {"orig_sen": "In a randomized controlled clinical trial, the abstinence rate at 1 year for patients using varencline was superior to that of patients in the group using bupropion SR (Zyban) and in the placebo group (11). ", "drug1": "varencline", "drug2": "bupropion SR", "polarity": ["false"]}, {"orig_sen": "In a randomized controlled clinical trial, the abstinence rate at 1 year for patients using varencline was superior to that of patients in the group using bupropion SR (Zyban) and in the placebo group (11). ", "drug1": "varencline", "drug2": "Zyban", "polarity": ["false"]}, {"orig_sen": "In a randomized controlled clinical trial, the abstinence rate at 1 year for patients using varencline was superior to that of patients in the group using bupropion SR (Zyban) and in the placebo group (11). ", "drug1": "bupropion SR", "drug2": "Zyban", "polarity": ["false"]}, {"orig_sen": "Varenicline reduces nicotine withdrawal symptoms, cigarette craving and nicotine satisfaction. ", "drug1": "Varenicline", "drug2": "nicotine", "polarity": ["false", "false"]}, {"orig_sen": "Varenicline reduces nicotine withdrawal symptoms, cigarette craving and nicotine satisfaction. ", "drug1": "nicotine", "drug2": "nicotine", "polarity": ["false"]}, {"orig_sen": "Combining with cisplatin and MWCHCP caused a tendency of increasing the tumor growth inhibition rate and significant attenution of cisplatin-induced diarrhea, visceral organ injury, gastric mucosal injury and decreased TNF-alpha mRNA level of intestine. ", "drug1": "cisplatin", "drug2": "cisplatin", "polarity": ["false"]}, {"orig_sen": "The present findings suggest that MWCHCP increases the inhibition rate of tumor growth of cisplatin and has a beneficial influence on gastrointestinal lesion induced by cisplatin.", "drug1": "cisplatin", "drug2": "cisplatin", "polarity": ["false"]}, {"orig_sen": "This complex has a unique ability to deliver bio-available calcium and phosphate when they are needed most. ", "drug1": "calcium", "drug2": "phosphate", "polarity": ["false"]}, {"orig_sen": "The purpose of this study was to investigate both the effect and mechanisms of IGF1R inhibition by tyrphostin AG1024 in the presence or absence of doxorubicin in a panel of six osteosarcoma cell lines and a self-established doxorubicin-resistant cell line. ", "drug1": "tyrphostin AG1024", "drug2": "doxorubicin", "polarity": ["false", "false"]}, {"orig_sen": "The purpose of this study was to investigate both the effect and mechanisms of IGF1R inhibition by tyrphostin AG1024 in the presence or absence of doxorubicin in a panel of six osteosarcoma cell lines and a self-established doxorubicin-resistant cell line. ", "drug1": "doxorubicin", "drug2": "doxorubicin", "polarity": ["false"]}, {"orig_sen": "Different chemical structures of precursors, smoking dynamics, pyrolysis of phytocannabinoids and frequency of drug use affect the amount of THC absorbed. ", "drug1": "phytocannabinoids", "drug2": "THC", "polarity": ["false"]}, {"orig_sen": "Pharmacological effects of other cannabinoids or medication on the pharmacokinetics of THC have not yet been studied in detail. ", "drug1": "cannabinoids", "drug2": "THC", "polarity": ["false"]}, {"orig_sen": "[Cyclooxygenase inhibitors and antiplatelet effect of acetylsalicylic acid. selective approach to nonsteroidal anti-inflammatory drugs in cardiological practice].\r\n", "drug1": "Cyclooxygenase inhibitors", "drug2": "acetylsalicylic acid", "polarity": ["false"]}, {"orig_sen": "[Cyclooxygenase inhibitors and antiplatelet effect of acetylsalicylic acid. selective approach to nonsteroidal anti-inflammatory drugs in cardiological practice].\r\n", "drug1": "Cyclooxygenase inhibitors", "drug2": "nonsteroidal anti-inflammatory drugs", "polarity": ["false"]}, {"orig_sen": "[Cyclooxygenase inhibitors and antiplatelet effect of acetylsalicylic acid. selective approach to nonsteroidal anti-inflammatory drugs in cardiological practice].\r\n", "drug1": "acetylsalicylic acid", "drug2": "nonsteroidal anti-inflammatory drugs", "polarity": ["false"]}, {"orig_sen": "Nonsteroidal anti-inflammatory drugs (NSAIDs) represent class of medicines which is wide concerning chemical structure and mechanism of action. ", "drug1": "Nonsteroidal anti-inflammatory drugs", "drug2": "NSAIDs", "polarity": ["false"]}, {"orig_sen": "In the light of contradictory data on efficacy and safety of NSAID in cardiovascular patients selection of most appropriate NSAID (basing on profile of efficacy and safety) in patients receiving continuous therapy with low dose aspirin appears to be a problem. ", "drug1": "NSAID", "drug2": "NSAID", "polarity": ["false"]}, {"orig_sen": "In the light of contradictory data on efficacy and safety of NSAID in cardiovascular patients selection of most appropriate NSAID (basing on profile of efficacy and safety) in patients receiving continuous therapy with low dose aspirin appears to be a problem. ", "drug1": "NSAID", "drug2": "aspirin", "polarity": ["false", "false"]}, {"orig_sen": "In this paper we discuss peculiarities of drug interaction between cyclooxygenase inhibitors and acetylsalicylic acid, and principles of selection of adequate NSAI.", "drug1": "cyclooxygenase inhibitors", "drug2": "acetylsalicylic acid", "polarity": ["false"]}, {"orig_sen": "In this paper we discuss peculiarities of drug interaction between cyclooxygenase inhibitors and acetylsalicylic acid, and principles of selection of adequate NSAI.", "drug1": "cyclooxygenase inhibitors", "drug2": "NSAI", "polarity": ["false"]}, {"orig_sen": "In this paper we discuss peculiarities of drug interaction between cyclooxygenase inhibitors and acetylsalicylic acid, and principles of selection of adequate NSAI.", "drug1": "acetylsalicylic acid", "drug2": "NSAI", "polarity": ["false"]}, {"orig_sen": "A fatal poisoning case involving etizolam, phenobarbital, promethazine and chlorpromazine is presented. ", "drug1": "etizolam", "drug2": "phenobarbital", "polarity": ["false"]}, {"orig_sen": "A fatal poisoning case involving etizolam, phenobarbital, promethazine and chlorpromazine is presented. ", "drug1": "etizolam", "drug2": "promethazine", "polarity": ["false"]}, {"orig_sen": "A fatal poisoning case involving etizolam, phenobarbital, promethazine and chlorpromazine is presented. ", "drug1": "etizolam", "drug2": "chlorpromazine", "polarity": ["false"]}, {"orig_sen": "A fatal poisoning case involving etizolam, phenobarbital, promethazine and chlorpromazine is presented. ", "drug1": "phenobarbital", "drug2": "promethazine", "polarity": ["false"]}, {"orig_sen": "A fatal poisoning case involving etizolam, phenobarbital, promethazine and chlorpromazine is presented. ", "drug1": "phenobarbital", "drug2": "chlorpromazine", "polarity": ["false"]}, {"orig_sen": "A fatal poisoning case involving etizolam, phenobarbital, promethazine and chlorpromazine is presented. ", "drug1": "promethazine", "drug2": "chlorpromazine", "polarity": ["false"]}, {"orig_sen": "Quantitative toxicological analysis showed that the concentrations of etizolam, phenobarbital, promethazine and chlorpromazine in the femoral blood were 86 ng/ml, 5082 microg/ml, 0.107 microg/ml and 0.144 microg/ml, respectively, and large amounts of drugs were also detected in the stomach contents. ", "drug1": "etizolam", "drug2": "phenobarbital", "polarity": ["false"]}, {"orig_sen": "Quantitative toxicological analysis showed that the concentrations of etizolam, phenobarbital, promethazine and chlorpromazine in the femoral blood were 86 ng/ml, 5082 microg/ml, 0.107 microg/ml and 0.144 microg/ml, respectively, and large amounts of drugs were also detected in the stomach contents. ", "drug1": "etizolam", "drug2": "promethazine", "polarity": ["false"]}, {"orig_sen": "Quantitative toxicological analysis showed that the concentrations of etizolam, phenobarbital, promethazine and chlorpromazine in the femoral blood were 86 ng/ml, 5082 microg/ml, 0.107 microg/ml and 0.144 microg/ml, respectively, and large amounts of drugs were also detected in the stomach contents. ", "drug1": "etizolam", "drug2": "chlorpromazine", "polarity": ["false"]}, {"orig_sen": "Quantitative toxicological analysis showed that the concentrations of etizolam, phenobarbital, promethazine and chlorpromazine in the femoral blood were 86 ng/ml, 5082 microg/ml, 0.107 microg/ml and 0.144 microg/ml, respectively, and large amounts of drugs were also detected in the stomach contents. ", "drug1": "phenobarbital", "drug2": "promethazine", "polarity": ["false"]}, {"orig_sen": "Quantitative toxicological analysis showed that the concentrations of etizolam, phenobarbital, promethazine and chlorpromazine in the femoral blood were 86 ng/ml, 5082 microg/ml, 0.107 microg/ml and 0.144 microg/ml, respectively, and large amounts of drugs were also detected in the stomach contents. ", "drug1": "phenobarbital", "drug2": "chlorpromazine", "polarity": ["false"]}, {"orig_sen": "Quantitative toxicological analysis showed that the concentrations of etizolam, phenobarbital, promethazine and chlorpromazine in the femoral blood were 86 ng/ml, 5082 microg/ml, 0.107 microg/ml and 0.144 microg/ml, respectively, and large amounts of drugs were also detected in the stomach contents. ", "drug1": "promethazine", "drug2": "chlorpromazine", "polarity": ["false"]}, {"orig_sen": "Standard antibiotic such as Gentamicin (10 microg), Cephalothin (30 microg), Ceftriaxone (10 microg), Nystatin (10 U) discs were used for comparison with the antimicrobial activities of essential oils of these plants. ", "drug1": "antibiotic", "drug2": "Gentamicin", "polarity": ["false"]}, {"orig_sen": "Standard antibiotic such as Gentamicin (10 microg), Cephalothin (30 microg), Ceftriaxone (10 microg), Nystatin (10 U) discs were used for comparison with the antimicrobial activities of essential oils of these plants. ", "drug1": "antibiotic", "drug2": "Cephalothin", "polarity": ["false"]}, {"orig_sen": "Standard antibiotic such as Gentamicin (10 microg), Cephalothin (30 microg), Ceftriaxone (10 microg), Nystatin (10 U) discs were used for comparison with the antimicrobial activities of essential oils of these plants. ", "drug1": "antibiotic", "drug2": "Ceftriaxone", "polarity": ["false"]}, {"orig_sen": "Standard antibiotic such as Gentamicin (10 microg), Cephalothin (30 microg), Ceftriaxone (10 microg), Nystatin (10 U) discs were used for comparison with the antimicrobial activities of essential oils of these plants. ", "drug1": "antibiotic", "drug2": "Nystatin", "polarity": ["false"]}, {"orig_sen": "Standard antibiotic such as Gentamicin (10 microg), Cephalothin (30 microg), Ceftriaxone (10 microg), Nystatin (10 U) discs were used for comparison with the antimicrobial activities of essential oils of these plants. ", "drug1": "Gentamicin", "drug2": "Cephalothin", "polarity": ["false"]}, {"orig_sen": "Standard antibiotic such as Gentamicin (10 microg), Cephalothin (30 microg), Ceftriaxone (10 microg), Nystatin (10 U) discs were used for comparison with the antimicrobial activities of essential oils of these plants. ", "drug1": "Gentamicin", "drug2": "Ceftriaxone", "polarity": ["false"]}, {"orig_sen": "Standard antibiotic such as Gentamicin (10 microg), Cephalothin (30 microg), Ceftriaxone (10 microg), Nystatin (10 U) discs were used for comparison with the antimicrobial activities of essential oils of these plants. ", "drug1": "Gentamicin", "drug2": "Nystatin", "polarity": ["false"]}, {"orig_sen": "Standard antibiotic such as Gentamicin (10 microg), Cephalothin (30 microg), Ceftriaxone (10 microg), Nystatin (10 U) discs were used for comparison with the antimicrobial activities of essential oils of these plants. ", "drug1": "Cephalothin", "drug2": "Ceftriaxone", "polarity": ["false"]}, {"orig_sen": "Standard antibiotic such as Gentamicin (10 microg), Cephalothin (30 microg), Ceftriaxone (10 microg), Nystatin (10 U) discs were used for comparison with the antimicrobial activities of essential oils of these plants. ", "drug1": "Cephalothin", "drug2": "Nystatin", "polarity": ["false"]}, {"orig_sen": "Standard antibiotic such as Gentamicin (10 microg), Cephalothin (30 microg), Ceftriaxone (10 microg), Nystatin (10 U) discs were used for comparison with the antimicrobial activities of essential oils of these plants. ", "drug1": "Ceftriaxone", "drug2": "Nystatin", "polarity": ["false"]}, {"orig_sen": "Evaluation of hepatic clearance and drug-drug interactions of luteolin and apigenin by using primary cultured rat hepatocytes.\r\n", "drug1": "luteolin", "drug2": "apigenin", "polarity": ["false"]}, {"orig_sen": "The hepatic clearance and drug-drug interactions of luteolin and apigenin were studied by using primary cultured rat hepatocytes. ", "drug1": "luteolin", "drug2": "apigenin", "polarity": ["false"]}, {"orig_sen": "Luteolin and apigenin experienced extensive first-pass metabolism. ", "drug1": "Luteolin", "drug2": "apigenin", "polarity": ["false"]}, {"orig_sen": "The elimination percent of luteolin and apigenin was found to be 91.9% and 86.7% after 120 min of incubation. ", "drug1": "luteolin", "drug2": "apigenin", "polarity": ["false"]}, {"orig_sen": "The predicted % liver blood flow was 82.3% and 85.4% for luteolin and apigenin, respectively. ", "drug1": "luteolin", "drug2": "apigenin", "polarity": ["false"]}, {"orig_sen": "Compared with the elimination of pure luteolin and apigenin, the elimination of luteolin and apigenin was much lower in hydrolyzed Flos Chrysanthemi extract (FCE) containing comparable amounts of luteolin and apigenin. ", "drug1": "luteolin", "drug2": "apigenin", "polarity": ["false", "false", "false", "false", "false", "false"]}, {"orig_sen": "Compared with the elimination of pure luteolin and apigenin, the elimination of luteolin and apigenin was much lower in hydrolyzed Flos Chrysanthemi extract (FCE) containing comparable amounts of luteolin and apigenin. ", "drug1": "luteolin", "drug2": "luteolin", "polarity": ["false", "false", "false"]}, {"orig_sen": "Compared with the elimination of pure luteolin and apigenin, the elimination of luteolin and apigenin was much lower in hydrolyzed Flos Chrysanthemi extract (FCE) containing comparable amounts of luteolin and apigenin. ", "drug1": "apigenin", "drug2": "luteolin", "polarity": ["false", "false", "false"]}, {"orig_sen": "Compared with the elimination of pure luteolin and apigenin, the elimination of luteolin and apigenin was much lower in hydrolyzed Flos Chrysanthemi extract (FCE) containing comparable amounts of luteolin and apigenin. ", "drug1": "apigenin", "drug2": "apigenin", "polarity": ["false", "false", "false"]}, {"orig_sen": "The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ", "drug1": "flavonoids", "drug2": "flavonols", "polarity": ["false"]}, {"orig_sen": "The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ", "drug1": "flavonoids", "drug2": "flavones", "polarity": ["false"]}, {"orig_sen": "The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ", "drug1": "flavonoids", "drug2": "isoflavone", "polarity": ["false"]}, {"orig_sen": "The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ", "drug1": "flavonoids", "drug2": "flavanone", "polarity": ["false"]}, {"orig_sen": "The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ", "drug1": "flavonoids", "drug2": "flavanonols", "polarity": ["false"]}, {"orig_sen": "The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ", "drug1": "flavonoids", "drug2": "catechins", "polarity": ["false"]}, {"orig_sen": "The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ", "drug1": "flavonoids", "drug2": "luteolin", "polarity": ["false"]}, {"orig_sen": "The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ", "drug1": "flavonoids", "drug2": "apigenin", "polarity": ["false"]}, {"orig_sen": "The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ", "drug1": "flavonols", "drug2": "flavones", "polarity": ["false"]}, {"orig_sen": "The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ", "drug1": "flavonols", "drug2": "isoflavone", "polarity": ["false"]}, {"orig_sen": "The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ", "drug1": "flavonols", "drug2": "flavanone", "polarity": ["false"]}, {"orig_sen": "The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ", "drug1": "flavonols", "drug2": "flavanonols", "polarity": ["false"]}, {"orig_sen": "The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ", "drug1": "flavonols", "drug2": "catechins", "polarity": ["false"]}, {"orig_sen": "The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ", "drug1": "flavonols", "drug2": "luteolin", "polarity": ["false"]}, {"orig_sen": "The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ", "drug1": "flavonols", "drug2": "apigenin", "polarity": ["false"]}, {"orig_sen": "The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ", "drug1": "flavones", "drug2": "isoflavone", "polarity": ["false"]}, {"orig_sen": "The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ", "drug1": "flavones", "drug2": "flavanone", "polarity": ["false"]}, {"orig_sen": "The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ", "drug1": "flavones", "drug2": "flavanonols", "polarity": ["false"]}, {"orig_sen": "The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ", "drug1": "flavones", "drug2": "catechins", "polarity": ["false"]}, {"orig_sen": "The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ", "drug1": "flavones", "drug2": "luteolin", "polarity": ["false"]}, {"orig_sen": "The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ", "drug1": "flavones", "drug2": "apigenin", "polarity": ["false"]}, {"orig_sen": "The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ", "drug1": "isoflavone", "drug2": "flavanone", "polarity": ["false"]}, {"orig_sen": "The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ", "drug1": "isoflavone", "drug2": "flavanonols", "polarity": ["false"]}, {"orig_sen": "The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ", "drug1": "isoflavone", "drug2": "catechins", "polarity": ["false"]}, {"orig_sen": "The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ", "drug1": "isoflavone", "drug2": "luteolin", "polarity": ["false"]}, {"orig_sen": "The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ", "drug1": "isoflavone", "drug2": "apigenin", "polarity": ["false"]}, {"orig_sen": "The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ", "drug1": "flavanone", "drug2": "flavanonols", "polarity": ["false"]}, {"orig_sen": "The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ", "drug1": "flavanone", "drug2": "catechins", "polarity": ["false"]}, {"orig_sen": "The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ", "drug1": "flavanone", "drug2": "luteolin", "polarity": ["false"]}, {"orig_sen": "The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ", "drug1": "flavanone", "drug2": "apigenin", "polarity": ["false"]}, {"orig_sen": "The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ", "drug1": "flavanonols", "drug2": "catechins", "polarity": ["false"]}, {"orig_sen": "The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ", "drug1": "flavanonols", "drug2": "luteolin", "polarity": ["false"]}, {"orig_sen": "The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ", "drug1": "flavanonols", "drug2": "apigenin", "polarity": ["false"]}, {"orig_sen": "The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ", "drug1": "catechins", "drug2": "luteolin", "polarity": ["false"]}, {"orig_sen": "The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ", "drug1": "catechins", "drug2": "apigenin", "polarity": ["false"]}, {"orig_sen": "The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. ", "drug1": "luteolin", "drug2": "apigenin", "polarity": ["false"]}, {"orig_sen": "Evaluation of antidepressant like activity of curcumin and its combination with fluoxetine and imipramine: an acute and chronic study.\r\n", "drug1": "curcumin", "drug2": "fluoxetine", "polarity": ["false"]}, {"orig_sen": "Evaluation of antidepressant like activity of curcumin and its combination with fluoxetine and imipramine: an acute and chronic study.\r\n", "drug1": "curcumin", "drug2": "imipramine", "polarity": ["false"]}, {"orig_sen": "Evaluation of antidepressant like activity of curcumin and its combination with fluoxetine and imipramine: an acute and chronic study.\r\n", "drug1": "fluoxetine", "drug2": "imipramine", "polarity": ["false"]}, {"orig_sen": "In the present study, the antidepressant like activity of curcumin and its combination with fluoxetine and imipramine was studied in acute model (three doses 24, 5 and 1 h before test) of forced swimming test (FST) in glass jar and tail suspension test (TST) in mice and in chronic model (14 day study) of FST with water wheel in rats. ", "drug1": "curcumin", "drug2": "fluoxetine", "polarity": ["false"]}, {"orig_sen": "In the present study, the antidepressant like activity of curcumin and its combination with fluoxetine and imipramine was studied in acute model (three doses 24, 5 and 1 h before test) of forced swimming test (FST) in glass jar and tail suspension test (TST) in mice and in chronic model (14 day study) of FST with water wheel in rats. ", "drug1": "curcumin", "drug2": "imipramine", "polarity": ["false"]}, {"orig_sen": "In the present study, the antidepressant like activity of curcumin and its combination with fluoxetine and imipramine was studied in acute model (three doses 24, 5 and 1 h before test) of forced swimming test (FST) in glass jar and tail suspension test (TST) in mice and in chronic model (14 day study) of FST with water wheel in rats. ", "drug1": "fluoxetine", "drug2": "imipramine", "polarity": ["false"]}, {"orig_sen": "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). ", "drug1": "curcumin", "drug2": "curcumin", "polarity": ["false", "false", "false", "false", "false", "false"]}, {"orig_sen": "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). ", "drug1": "curcumin", "drug2": "fluoxetine", "polarity": ["false", "false", "false", "false", "false"]}, {"orig_sen": "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). ", "drug1": "curcumin", "drug2": "imipramine", "polarity": ["false", "false", "false", "false", "false", "false"]}, {"orig_sen": "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). ", "drug1": "fluoxetine", "drug2": "imipramine", "polarity": ["false", "false", "false"]}, {"orig_sen": "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). ", "drug1": "fluoxetine", "drug2": "curcumin", "polarity": ["false", "false", "false"]}, {"orig_sen": "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). ", "drug1": "fluoxetine", "drug2": "fluoxetine", "polarity": ["false"]}, {"orig_sen": "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). ", "drug1": "imipramine", "drug2": "curcumin", "polarity": ["false", "false"]}, {"orig_sen": "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). ", "drug1": "imipramine", "drug2": "fluoxetine", "polarity": ["false"]}, {"orig_sen": "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). ", "drug1": "imipramine", "drug2": "imipramine", "polarity": ["false"]}, {"orig_sen": "The effect of curcumin (100 mg/kg) was similar to that of fluoxetine and imipramine (p > 0.05) but its addition to fluoxetine and imipramine did not improve their antidepressant activity (p > 0.05). ", "drug1": "curcumin", "drug2": "fluoxetine", "polarity": ["false", "false"]}, {"orig_sen": "The effect of curcumin (100 mg/kg) was similar to that of fluoxetine and imipramine (p > 0.05) but its addition to fluoxetine and imipramine did not improve their antidepressant activity (p > 0.05). ", "drug1": "curcumin", "drug2": "imipramine", "polarity": ["false", "false"]}, {"orig_sen": "The effect of curcumin (100 mg/kg) was similar to that of fluoxetine and imipramine (p > 0.05) but its addition to fluoxetine and imipramine did not improve their antidepressant activity (p > 0.05). ", "drug1": "fluoxetine", "drug2": "imipramine", "polarity": ["false", "false", "false"]}, {"orig_sen": "The effect of curcumin (100 mg/kg) was similar to that of fluoxetine and imipramine (p > 0.05) but its addition to fluoxetine and imipramine did not improve their antidepressant activity (p > 0.05). ", "drug1": "fluoxetine", "drug2": "fluoxetine", "polarity": ["false"]}, {"orig_sen": "The effect of curcumin (100 mg/kg) was similar to that of fluoxetine and imipramine (p > 0.05) but its addition to fluoxetine and imipramine did not improve their antidepressant activity (p > 0.05). ", "drug1": "imipramine", "drug2": "fluoxetine", "polarity": ["false"]}, {"orig_sen": "The effect of curcumin (100 mg/kg) was similar to that of fluoxetine and imipramine (p > 0.05) but its addition to fluoxetine and imipramine did not improve their antidepressant activity (p > 0.05). ", "drug1": "imipramine", "drug2": "imipramine", "polarity": ["false"]}, {"orig_sen": "Curcumin can be a useful antidepressant especially in cases which respond to drugs having mixed effects on serotonin and catecholamines levels in the brain.", "drug1": "Curcumin", "drug2": "antidepressant", "polarity": ["false"]}, {"orig_sen": "PXR-ligands include a wide variety of pharmaceutical agents, such as antiepileptic drugs, taxol, rifampicin, and human immunodeficiency virus protease inhibitors such as ritonavir and saquinavir. ", "drug1": "antiepileptic drugs", "drug2": "taxol", "polarity": ["false"]}, {"orig_sen": "PXR-ligands include a wide variety of pharmaceutical agents, such as antiepileptic drugs, taxol, rifampicin, and human immunodeficiency virus protease inhibitors such as ritonavir and saquinavir. ", "drug1": "antiepileptic drugs", "drug2": "rifampicin", "polarity": ["false"]}, {"orig_sen": "PXR-ligands include a wide variety of pharmaceutical agents, such as antiepileptic drugs, taxol, rifampicin, and human immunodeficiency virus protease inhibitors such as ritonavir and saquinavir. ", "drug1": "antiepileptic drugs", "drug2": "human immunodeficiency virus protease inhibitors", "polarity": ["false"]}, {"orig_sen": "PXR-ligands include a wide variety of pharmaceutical agents, such as antiepileptic drugs, taxol, rifampicin, and human immunodeficiency virus protease inhibitors such as ritonavir and saquinavir. ", "drug1": "antiepileptic drugs", "drug2": "ritonavir", "polarity": ["false"]}, {"orig_sen": "PXR-ligands include a wide variety of pharmaceutical agents, such as antiepileptic drugs, taxol, rifampicin, and human immunodeficiency virus protease inhibitors such as ritonavir and saquinavir. ", "drug1": "antiepileptic drugs", "drug2": "saquinavir", "polarity": ["false"]}, {"orig_sen": "PXR-ligands include a wide variety of pharmaceutical agents, such as antiepileptic drugs, taxol, rifampicin, and human immunodeficiency virus protease inhibitors such as ritonavir and saquinavir. ", "drug1": "taxol", "drug2": "rifampicin", "polarity": ["false"]}, {"orig_sen": "PXR-ligands include a wide variety of pharmaceutical agents, such as antiepileptic drugs, taxol, rifampicin, and human immunodeficiency virus protease inhibitors such as ritonavir and saquinavir. ", "drug1": "taxol", "drug2": "human immunodeficiency virus protease inhibitors", "polarity": ["false"]}, {"orig_sen": "PXR-ligands include a wide variety of pharmaceutical agents, such as antiepileptic drugs, taxol, rifampicin, and human immunodeficiency virus protease inhibitors such as ritonavir and saquinavir. ", "drug1": "taxol", "drug2": "ritonavir", "polarity": ["false"]}, {"orig_sen": "PXR-ligands include a wide variety of pharmaceutical agents, such as antiepileptic drugs, taxol, rifampicin, and human immunodeficiency virus protease inhibitors such as ritonavir and saquinavir. ", "drug1": "taxol", "drug2": "saquinavir", "polarity": ["false"]}, {"orig_sen": "PXR-ligands include a wide variety of pharmaceutical agents, such as antiepileptic drugs, taxol, rifampicin, and human immunodeficiency virus protease inhibitors such as ritonavir and saquinavir. ", "drug1": "rifampicin", "drug2": "human immunodeficiency virus protease inhibitors", "polarity": ["false"]}, {"orig_sen": "PXR-ligands include a wide variety of pharmaceutical agents, such as antiepileptic drugs, taxol, rifampicin, and human immunodeficiency virus protease inhibitors such as ritonavir and saquinavir. ", "drug1": "rifampicin", "drug2": "ritonavir", "polarity": ["false"]}, {"orig_sen": "PXR-ligands include a wide variety of pharmaceutical agents, such as antiepileptic drugs, taxol, rifampicin, and human immunodeficiency virus protease inhibitors such as ritonavir and saquinavir. ", "drug1": "rifampicin", "drug2": "saquinavir", "polarity": ["false"]}, {"orig_sen": "PXR-ligands include a wide variety of pharmaceutical agents, such as antiepileptic drugs, taxol, rifampicin, and human immunodeficiency virus protease inhibitors such as ritonavir and saquinavir. ", "drug1": "human immunodeficiency virus protease inhibitors", "drug2": "ritonavir", "polarity": ["false"]}, {"orig_sen": "PXR-ligands include a wide variety of pharmaceutical agents, such as antiepileptic drugs, taxol, rifampicin, and human immunodeficiency virus protease inhibitors such as ritonavir and saquinavir. ", "drug1": "human immunodeficiency virus protease inhibitors", "drug2": "saquinavir", "polarity": ["false"]}, {"orig_sen": "PXR-ligands include a wide variety of pharmaceutical agents, such as antiepileptic drugs, taxol, rifampicin, and human immunodeficiency virus protease inhibitors such as ritonavir and saquinavir. ", "drug1": "ritonavir", "drug2": "saquinavir", "polarity": ["false"]}, {"orig_sen": "Beside this, the medication oriented supplementation of vitamin D can also ameliorate the pharmacologic action of many drugs, such as bisphosphonates, statins and cytostatic drugs.", "drug1": "vitamin D", "drug2": "bisphosphonates", "polarity": ["false"]}, {"orig_sen": "Beside this, the medication oriented supplementation of vitamin D can also ameliorate the pharmacologic action of many drugs, such as bisphosphonates, statins and cytostatic drugs.", "drug1": "vitamin D", "drug2": "statins", "polarity": ["false"]}, {"orig_sen": "Beside this, the medication oriented supplementation of vitamin D can also ameliorate the pharmacologic action of many drugs, such as bisphosphonates, statins and cytostatic drugs.", "drug1": "vitamin D", "drug2": "cytostatic drugs", "polarity": ["false"]}, {"orig_sen": "Beside this, the medication oriented supplementation of vitamin D can also ameliorate the pharmacologic action of many drugs, such as bisphosphonates, statins and cytostatic drugs.", "drug1": "bisphosphonates", "drug2": "statins", "polarity": ["false"]}, {"orig_sen": "Beside this, the medication oriented supplementation of vitamin D can also ameliorate the pharmacologic action of many drugs, such as bisphosphonates, statins and cytostatic drugs.", "drug1": "bisphosphonates", "drug2": "cytostatic drugs", "polarity": ["false"]}, {"orig_sen": "Beside this, the medication oriented supplementation of vitamin D can also ameliorate the pharmacologic action of many drugs, such as bisphosphonates, statins and cytostatic drugs.", "drug1": "statins", "drug2": "cytostatic drugs", "polarity": ["false"]}, {"orig_sen": "A rapid, sensitive and reliable high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method was developed and validated for the determination of propiverine hydrochloride (CAS 54556-98-8) in human plasma using cetirizine di-hydrochloride as internal standard (IS, CAS 8388-51-0). ", "drug1": "propiverine hydrochloride", "drug2": "cetirizine di-hydrochloride", "polarity": ["false"]}, {"orig_sen": "Following liquid-liquid extraction with ethyl acetate, the separation was performed on a reverse phase C18 column with a mobile phase consisted of methanol-ammonium acetate (pH 4.0; 10 mM) (70:30, v/v). ", "drug1": "ethyl acetate", "drug2": "methanol-ammonium acetate", "polarity": ["false"]}]